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Abstract
Human influenza viruses can be isolated efficiently from clinical samples using Madin-Darby canine kidney (MDCK)
cells. However, this process is known to induce mutations in the virus as it adapts to this non-human cell-line. We
performed a systematic study to record the pattern of MDCK-induced mutations observed across the whole influenza
A/H3N2 genome. Seventy-seven clinical samples collected from 2009-2011 were included in the study. Two full
influenza genomes were obtained for each sample: one from virus obtained directly from the clinical sample and one
from the matching isolate cultured in MDCK cells. Comparison of the full-genome sequences obtained from each of
these sources showed that 42% of the 77 isolates had acquired at least one MDCK-induced mutation. The presence
or absence of these mutations was independent of viral load or sample origin (in-patients versus out-patients).
Notably, all the five hemagglutinin missense mutations were observed at the hemaggutinin 1 domain only, particularly
within or proximal to the receptor binding sites and antigenic site of the virus. Furthermore, 23% of the 77 isolates
had undergone a MDCK-induced missense mutation, D151G/N, in the neuraminidase segment. This mutation has
been found to be associated with reduced drug sensitivity towards the neuraminidase inhibitors and increased viral
receptor binding efficiency to host cells. In contrast, none of the neuraminidase sequences obtained directly from the
clinical samples contained the D151G/N mutation, suggesting that this mutation may be an indicator of MDCK
culture-induced changes. These D151 mutations can confound the interpretation of the hemagglutination inhibition
assay and neuraminidase inhibitor resistance results when these are based on MDCK isolates. Such isolates are
currently in routine use in the WHO influenza vaccine and drug-resistance surveillance programs. Potential data
interpretation miscalls can therefore be avoided by careful exclusion of such D151 mutants after further sequence
analysis.
Citation: Lee HK, Tang JW-T, Kong DH-L, Loh TP, Chiang DK-L, et al. (2013) Comparison of Mutation Patterns in Full-Genome A/H3N2 Influenza
Sequences Obtained Directly from Clinical Samples and the Same Samples after a Single MDCK Passage. PLoS ONE 8(11): e79252. doi:10.1371/
journal.pone.0079252
Editor: Paul Digard, University of Edinburgh, United Kingdom
Received June 28, 2013; Accepted September 19, 2013; Published November 1, 2013
Copyright: © 2013 Lee et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by the National Medical Research Council grant funding (ref number: NMRC/1247/2010 to JWT and ESK; http://
www.nmrc.gov.sg/content/nmrc_internet/home.html). The funders had no role in study design, data collection and analysis, decision to publish, or
preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
* E-mail: julian.tang@albertahealthservices.ca (JW-TT); evelyn_koay@nuhs.edu.sg (ES-CK)
Introduction
Influenza viruses obtained from infected human host
specimens can be isolated using several different cell-lines.
They include embryonated chicken eggs, in vitro monolayers of
primary cell-line: rhesus monkey kidney (RhMK), and
established continuous cell-lines: the African green monkey
kidney (AGMK/Vero), Madin-Darby canine kidney (MDCK),
mink lung epithelial (Mv1Lu), rhesus monkey kidney (LLC
MK2), and buffalo green monkey kidney (BGMK) cell-lines [1].
Among these, the MDCK cells have been used extensively in
various clinical diagnostic [1] and research [2-5] investigations
of influenza viruses. It is particularly useful for the amplification
of influenza viruses found in clinical samples [6] to produce
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sufficient amounts of virus for experimental research and
distribution to other research laboratories [7-10].
Host-induced mutations induced during viral passaging have
been reported sporadically [5,8,11-15]. Yet, despite the
extensive use of MDCK cells in influenza research, there are
no systematic studies of possible MDCK-induced mutations
across the whole influenza genome. Only a few reports of
MDCK-induced mutations in individual gene segments have
been published [12,14,16]. These MDCK-induced mutations
may have direct and significant impact on the data
interpretation in studies related to viral molecular epidemiology
[11], antigenicity and pathogenicity [7], and patterns of drug
resistance [8-10,12,14]. For these studies, only the
hemagglutinin (HA), neuraminidase (NA), and matrix protein
(MP) genes were routinely sequenced [5,11,17]. An accurate
characterization of the pattern of MDCK-induced mutations
across the whole genome would improve the quality and
accuracy of data interpretation of influenza virus mutation
studies.
In this study, we performed an extensive genome sequence
comparison between influenza A/H3N2 viral sequences
obtained: 1) directly from, and 2) after isolation in MDCK cells,
from each of the clinical respiratory samples.
Results
Viral culturing and sequencing
A total of 77 influenza A/H3N2 clinical samples with cycle
threshold (Ct) values of 15.34-33.22 (mean: 23.91; SD: 3.89)
were included in this analysis. For each of these samples, two
full influenza genomes were obtained: one from virus obtained
directly from the clinical sample and one from virus that was
cultured once in the MDCK cell-line. These relatively high viral
load samples (Ct < 33.22; > 408 viral copies/μL of RNA extract)
were used to permit full genome sequences to be obtained
from both of these virus sources.
In addition, to test the reproducibility of the pattern of MDCK-
cultured viral sequences, 20 replicates of a clinical sample with
a high viral load (7x106 viral copies/μL of RNA extract) of
influenza A/Singapore/H2011.704/2011(H3N2) was cultured
simultaneously. All cultured samples analyzed in this study had
only single passage history.
The complete genome sequences of all the paired clinical
and cultured influenza A/H3N2 (n= 77 direct from source + 77
MDCK-cultured = 154) were generated and subjected to an
exhaustive phylogenetic analysis to screen for any artifacts
and/or sequence mosaics that may have been induced by the
sequencing and other laboratory methods or contaminants [18].
In brief, this was performed by running all of these sequences
through a suite of phylogenetic programs designed to detect
the presence of any recombination breakpoints in these
sequences, as described by Lam et al. (2013).
After completing these analyses, all of the sequences were
submitted to the NCBI GenBank. Twenty-one of the 154
genome sequences (7 from clinical samples and 14 from
isolates, from different strains) had been submitted earlier from
a previous study [19]; the remaining 133 genome sequences,
with accession codes of KF014126-KF015189, were submitted
in June 2013.
To evaluate the consistency of the Sanger method, the
extracted RNA from a clinical sample as well as a cultured
isolate with high viral loads were repeatedly sequenced - ten
replicates each. The results of these twenty replicate
experiments did not show any discrepancy in the sequence call
rate for each set of replicates.
Sequence comparison between clinical and MDCK-
cultured samples
Comparison of the full genome sequences between the
clinical sample and its corresponding isolate showed that 32
out of 77 (42%) isolates had undergone MDCK-induced
mutations. The affected nucleotide and amino acid (aa)
positions of each of the affected isolates (including
synonymous and missense changes) are summarized in the
Table 1.
Other than the recurrent mutations found in the HA and NA
segments, all individual missense mutations occurred just
once. The emergences of A138S, N165K, G218R, P221L, and
V223I were observed within the HA segment, particularly at the
HA1 domain (residues 1-328), with frequencies of 1, 1, 2, 3,
and 1, respectively. Out of the 77 isolates, amino acid changes
to N or G at position D151 were observed in the NA segment
with frequencies of 18 (23%), with the occurrence of D151N
and D151G recorded at frequencies of 11 (14%) and 7 (9%). In
contrast, none of the paired NA sequences obtained directly
from the viruses in the clinical samples contained this D151
mutation. All the patients with D151 MDCK-induced mutations
had no prior antiviral treatment history.
The results from the single sample that was cultured in
MDCK cells in 20 replicates, five (25%) had acquired one
MDCK-induced mutation, respectively: one T148T/I and two
D151D/N mutations in the NA segment, one R348K in the
nucleoprotein (NP) segment, and a synonymous mutation at
N312 of the polymerase basic 1 (PB1) segment.
Association with Ct values
The mean of the Ct of samples that developed MDCK-
induced mutations versus those that did not, were: 24.08
(range: 17.45-30.00) versus 23.79 (15.34-33.22), respectively.
There was no statistically significant difference (p = 0.745; 2
Sample T-test) in the Ct values between the samples that
contained and those that did not contain any MDCK-induced
mutations. This suggests that the presence or absence of
MDCK-induced mutations is not a viral load-dependent
phenomenon in these clinical influenza A/H3N2 positive
samples.
Association with sample sources
Out of the 77 cultured samples sequenced, 44 were
collected from hospitalized in-patients (n=37) or out-patients
(n=7) seen at a tertiary-care academic medical center, the
National University Hospital (NUH) of Singapore. The
remaining were samples received from its affiliated primary-
care clinics (n=33). No statistically significant difference (p =
0.0638; Fisher’s exact test) was found between the proportion
MDCK-Induced Mutations
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Table 1. Summary of MDCK-mediated mutations for each
of the affected influenza A/H3N2 virus isolates examined in
this study.
Strain ID
Nucleotide
changea Amino acid change
Segment 1/ polymerase basic
2 (PB2)   
C2011.422 2118A>R I697M
C2011.496 600A>M E191D
C2011.647 1287C>T F420c
 1362T>C L445c
H2009.518 1724A>T Q566L
H2010.619 1589Y>C I/T521T
H2010.822 2200C>Y L725c
H2011.507 2013T>W T662c
H2011.797 1836G>K M603I
Segment 4/ hemagglutinin
(HA)   
C2009.485a 572C>M N165N/Kb
C2011.301 739C>Y P221P/Lb
C2011.564 489G>K A138A/Sb
C2011.614 739C>Y P221P/Lb
H2009.679 729G>R G218G/Rb
H2010.559C 739C>Y P221P/Lb
 744G>R V223V/Ib
H2011.797 729G>R G218G/Rb
H2011.808bC 644G>R K189b,c
Segment 5/ nucleoprotein
(NP)   
C2011.471 123G>R R26c
H2010.822 1262C>Y T406T/I
H2011.570 1002C>Y N319c
Segment 6/ neuraminidase
(NA)   
C2009.863 268A>R E83c
 470G>R D151D/N
C2010.937V 121A>R T34c
 471A>R D151D/G
C2011.301 470G>R D151D/N
C2011.362V 470G>R D151D/N
C2011.452 470G>R D151D/N
C2011.471 470G>R D151D/N
C2011.477 470G>R D151D/N
C2011.493 471A>R D151D/G
C2011.496 470G>R D151D/N
C2011.507V 470G>R D151D/N
C2011.573 471A>R D151D/G
C2011.614 471A>R D151D/G
C2011.641 471A>R D151D/G
C2011.825 470G>R D151D/N
H2010.321C 470G>A D151N
H2010.559C 251T>Y C78C/R
H2010.797 471A>R D151D/G
H2011.463 1066G>R V349c
H2011.482 470G>R D151D/N
H2011.507 395C>Y P126P/S
H2011.570 471A>R D151D/G
of the samples containing MDCK-induced mutations collected
from the in-patients (11/37, 30%) and from the outpatients,
including those seen in the community primary-care clinics and
the hospital out-patients (21/40, 53%). The 7 hospital out-
patients were included with the community cohort because, in
essence, the patients attending both types of out-patient clinics
would have arrived in those clinics directly from the community
population.
Variation in residue 151 of NA in current influenza
deposits
A total of 7229 complete NA sequences of influenza A/H3N2
collected from 2004-2012 were downloaded from the GISAID
EpiFlu database (http://platform.gisaid.org/; last accessed 15
August 2013). The aa variations detected at residue D151 of
these NA sequences are summarized in Table 2. Of the 7229
NA sequences, 2729 (38%) and 736 (10%) were obtained from
MDCK-cultured isolates and primary clinical samples,
respectively.
Overall, the aa variations at position 151 on the NA
sequence were more commonly found in the MDCK-cultured
isolates. During the study period (2009-2011), the proportion of
D151 mutations in the MDCK-cultured viruses derived from the
EpiFlu database (327/1745, 19%) were similar to that detected
in this study (18/77, 23%) (p = 0.300). Of the D151 mutations
deposited in the EpiFlu database, 150 (9%) were D151N, 143
(8%) were D151G, and 34 (2%) were a mixture of both D151N
and D151G.
A total of 883 (32.4%) out of 2729 MDCK-cultured isolates
collected during 2004-2012 had an aa change at position 151.
By contrast, only 2 (0.3%) out of 736 clinical samples were
found to carry such aa change. The distribution of the
proportion of D151 mutation in the MDCK-cultured isolates
over year of sample collection showed climaxes reached in
Table 1 (continued).
Strain ID Nucleotide changeaAmino acid change
Segment 8/ non-structural
(NS)   
C2011.362V 592R>G NS1: D/G189G; NS2: I/V32V
C2011.573 578R>A NS2: G/D27D
H2010.559C 335C>Y NS1: F103c
Alternatively spliced mRNAs of the non-structural protein gene allows translation of
two alternate proteins, non-structural protein 1 (NS1) and non-structural/ nuclear
export protein (NS2/NEP). The non-ATCG letters coded for ambiguous/degenerate
nucleotide sequences, i.e. “R” - “A and G”, “M” – “A and C”, “Y” – “C and T”, “W” –
“A and T”, and “K” – “G and T”.
aNucleotide numbering based on influenza A/Singapore/C2009.458V/2009(H3N2),
GenBank accession: KF015129, KF014198, KF014597, KF014464, and
KF014730.
bAmino acid numbering without including signaling peptide (i.e. the first 16 amino
acids)
cChange of nucleotide or amino acid that resulted in synonymous mutation.
doi: 10.1371/journal.pone.0079252.t001
MDCK-Induced Mutations
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2007 and 2012 (Figure 1). A similar trend was observed from
the in-house MDCK-cultured isolates collected from 2009-2011
in this study.
Discussion
The results of this study demonstrate that in about 42% of
clinical samples containing seasonal human influenza A/H3N2
virus, culturing in MDCK cells can lead to the emergence of
variants carrying substitutions in most of the viral segments. To
our knowledge, this is the first extensive report that has
documented MDCK-induced mutation patterns at the whole
genome level for human influenza A/H3N2 obtained from
clinical diagnostic samples. The pairwise comparison of
genomic sequences generated from MDCK-cultured samples
and their matching primary clinical samples revealed a
sporadic pattern of mutations in PB2, NP, and NS segments
but not for the HA and NA segments (Table 1).
MDCK-induced changes in the HA protein
Interestingly, all five residue changes in HA protein were
found within the HA1 domain only. In particular, four out of the
five residue changes (A138S, G218R, P221L, and V223I) were
within or proximal to the receptor-binding sites, particularly at
the 130- and 220- loops [20,21]. The other (N165K) was
located at the antigenic site of the virus [21].
The A138S mutation can emerge in vivo in
immunocompromised patients and in vitro in MDCK cultures.
Both have been found to cause total loss of receptor binding
ability to the SAα2,3 Gal linkage [22-24]. Mutations at the HA1
218 position, which is in the vicinity of the receptor-binding site,
have also been reported to be associated with changes of
Figure 1.  Distribution of D151 mutations isolated from MDCK-cultured influenza A/H3N2 viruses, according to the year of
sample collection.  The white and black columns represent the percentages of D151 mutations in MDCK-cultured isolates
deposited in GISAID EpiFlu database (n=2729, 2004-2012) and from this study (n=77, 2009-2011), respectively. The relative trend
in an increasing proportion of in-house MDCK-cultured isolates collected from 2009-2011 is similar to that for the GISAID
sequences.
doi: 10.1371/journal.pone.0079252.g001
MDCK-Induced Mutations
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receptor-binding specificity [25], as well as increased viral
pathogenicity related to viremia leading to severe lung, spleen,
intestine, brain, and heart infections, when tested in a mouse
model [26]. In the similar study, the G218R mutation was found
to reduce the SAα2,6 Gal linkage-binding affinity [25].
The V223I mutation was found to be induced during the
passage of influenza viruses using embryonated chicken eggs
[27]. This mutation has been shown to reduce the binding of
HA, which seems to give it some resistance to the action of NA
inhibitors (NAIs) by allowing the virus to be released from cells
with less dependence on the NA enzyme [28]. However, this
may not be the complete explanation as an
immunocompromised child infected with a virus containing this
mutation was found to exhibit susceptibility to zanamivir [29].
To date, no published data about P221L is available yet in
the literature. However, the close proximity of this mutation to
the receptor-binding sites may suggest similar alterations on
receptor-binding specificity and/or affinity, as mentioned earlier.
The N165 residue, which is located on the membrane-distal
surface of HA, was identified as one of the oligosaccharide
attachment/glycosylation sites that determine the viral
antigenicity and assist in host-immune escape [30,31].
MDCK-induced changes in the NA protein
From 2009-2011, emergences of G and N at residue D151
were detected in the NA segment with a frequency of 18 out of
the 77 isolates (23%). Support for these findings is found in the
1745 EpiFlu MDCK-cultured sequences collected from the
same period, where a similar proportion, 327/1745 (19%)
demonstrated these same D151G/N mutations (p = 0.300).
This suggests that the D151G/N mutation may be a marker of
MDCK-cultured isolates, as noted previously [7,8], in
approximately 20% of the samples, although in the majority of
cultured isolates, this mutation is not present.
It is interesting to note that the number of MDCK-induced
mutations in these samples is similar to that induced in a single
sample split into 20 aliquots and cultured in MDCK cells (23%
vs 10%; p = 0.2278). However, only one sample was
investigated in this study and a larger number of samples
examined in this way in future studies will give a clearer
picture.
Residue D151, which serves as a proton donor in catalytic
activity and is associated with the active site of NA, is expected
to affect the enzymatic reaction of NAIs [32,33]. Substitution of
D151 to G or N was shown to decrease virus susceptibility to
the NAIs, i.e. oseltamivir, zanamivir, and peramivir [8-10,34].
Nonetheless, the D151G and D151N mutations conferred
different degrees of significantly enhanced resistance to the
three NAIs, when combined with H274Y (N2 numbering) or
H275Y (N1 numbering) mutation [8,9]. Thus, these mutations
induced during viral culture can give a false impression of drug
resistance during influenza virus surveillance.
Furthermore, substitution of D151 to G or N can change the
specificity of NA to gain receptor-binding capacity [7,35-37],
besides reducing its enzymatic ability to remove sialic acids
from both the SAα2,3 and SAα2,6 Gal-linked receptors of HA,
to enable release of progeny from infected cells [37]. This
additional acquired receptor-binding capacity can cause biased
results in the hemagglutinin inhibition assay [7,38], which is
frequently used by the WHO for antigenic monitoring for regular
vaccine update.
The finding of mixed populations in most of the MDCK-
isolates in our study (17/18, Table 1) is not totally unexpected
and may just indicate a gradual adaptation to a new host cell
species – further passages in the same cell-line would
eventually yield a pure population adapted to that cell-line.
In this study, the D151 mutations were found only in MDCK-
cultured isolates and not in the clinical samples. This
observation could be explained by two hypotheses. The clinical
samples may contain D151 mutant viruses at concentrations
too low to be detected by the Sanger method. In the MDCK
culture, these mutant viruses may be selectively amplified and
detected. This is supported by a previous study that found up
to 13% of D151 mutant population in a given clinical sample
using a pyrosequencing method [7], a concentration near the
detection limit of the Sanger method. On the other hand, it is
also possible that the D151 mutant was induced de novo in the
MDCK culture medium [8,11,12,39,40]. This latter hypothesis
was supported by the finding of only 2/736 (0.3%) of D151
mutant virus in the clinical sample (Table 2).
Most of the laboratories that contributed influenza genetic
sequences to the EpiFlu database used MDCK cell-lines for
influenza virus propagation (Table 2). Interestingly, despite the
differences in the number of passage history and potential
methodology differences, the proportion of D151 mutations
found in this study were similar to those deposited in the EpiFlu
database (Table 2).
MDCK-induced changes in the other viral proteins
Strikingly, no mutation was detected in the PA and MP gene
of all the samples tested. A single sporadic synonymous
mutation (N312) in the PB1 gene was observed in the 20
culture replicates of the influenza A/Singapore/
H2011.704/2011(H3N2) primary clinical sample, but none were
found in PB1 in the other individual, single culture pairwise
comparisons. Relatively few or no MDCK-induced mutations
were found in the MP, PA, and PB1 genes, suggesting that
these genes are not subject to MDCK-specific adaptation
selection pressures.
In a previous study, MDCK-induced mutations were reported
in the HA and MP genes with passage histories of 3 and 10,
respectively [16]. The mutations found included R83K, H183L,
H156N, R220G, V226I, R229G, R229I, and R229K in the HA1
protein; A147T, T147A, and G150E in the HA2 protein; A30T in
the ion channel matrix (M2) protein, but none of these
mutations were detected in this study. However, it should be
noted that our study employed a Sanger sequencing-based
approach that could only detect the mixed viral population of as
low as 10%, which could have missed the minorities that
existed in less than 10% proportions in the tested samples.
Primary clinical specimens collected directly from patients
vary in amount of viruses, depending on when the samples
were taken post-symptom onset [41]. Even so, our study
showed that the rate of MDCK-induced mutation did not
correlate with the viral titers (Ct values) of the clinical samples,
suggesting that this was more of a sporadic event, rather than
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one that was necessarily viral load dependent. This implies that
the MDCK-adapted mutations were not viral load (and
therefore viral replication) dependent.
In conclusion, apart from providing information on MDCK-
induced mutations, this study has provided further support for
the use of D151 as a marker of MDCK-cultured isolates. D151
can confound the interpretation of hemagglutinin inhibition and
drug resistance results when the isolate is obtained from
MDCK cultures, e.g. the WHO vaccine and drug-sensitivity
surveillance programs [10,38]. This may be overcome by the
exclusion of isolates with D151 mutations after genotyping.
Materials and Methods
Ethics statement
All research activities involving the use of these clinical
samples were reviewed and approved by the local institutional
ethics review board (National Healthcare Group: B/09/360 and
E/09/341). Waiver of consent was granted to this study under
the following conditions: (1) only leftover clinical samples,
initially submitted for diagnostic influenza testing, were used,
(2) no additional clinical sample was sought from the patients
for the purpose of this study (3), the clinical samples were fully
anonymized prior to the sequencing analysis, and the
anonymization was maintained during data analysis and
publication (4) the results of this study do not impact the clinical
management of these patients and are not shared with their
attending physicians
Clinical samples
Clinical samples collected in the form of nasopharyngeal,
nasal or throat swabs between May 2009 and October 2011
were processed and tested using a combination of clinically
validated reverse-transcription-polymerase chain reaction (RT-
PCR) assays [42,43]. The Ct values of the clinical samples
were determined using the in-house influenza A/B RT-PCR
assay that targets the MP gene [43]. These included samples
collected from patients who attended NUH or its affiliated
primary care clinics. In addition, the antiviral treatment histories
for patients with the D151 mutation were examined and
recorded.
MDCK culture
Influenza A/H3N2 clinical samples with Ct values less than
33.22 were included in this study and cultured using the
MDCK.2 (ATCC; CRL-2936) cell-line with a single passage
history. Trypsin-treated MDCK viral culturing was performed
with reference to CLSI Viral Culture; Approved Guideline [44].
Briefly, the shell vial monolayer of the culture was first rinsed
with 0.5 mL minimum essential media with 0.8% trypsin (TMM)
to remove traces of growth media. The clinical samples were
aspirated into a 5-mL sterile syringe and filtered through a
Minisart syringe filter of 0.45 μm pore size (Sartorius,
Goettingen, DE) directly into the MDCK monolayer shell vials,
followed by centrifugation of 760 relative centrifugal force for 30
minutes at 28 °C. The filtrates were decanted. The cell vial
cultures were maintained with 1 mL of TMM and incubated at
33 °C in 5% CO2 for up to 7 days, until the characteristic
influenza virus cytopathic effect was observed. For the 20
culture replicates, clinical sample influenza A/Singapore/
H2011.704/2011(H3N2), which contained a high viral load, was
diluted 50 with universal transport medium (Copan Diagnostics
Inc., Corona, CA) prior to culture.
Viral RNA
Viral RNA was extracted from 200 μL of clinical and cultured
samples with either the Qiagen EZ1 Virus mini kit v2.0 or the
QIAsymphony Virus/Bacteria mini kit, using their respective
proprietary Bio Robot EZ1 and QIAsymphony automated
platforms (Qiagen, Valencia, CA), according to the
manufacturer’s instructions. All extracted RNAs were eluted
into a final volume of 60 μL of elution buffer.
Whole genome sequencing
Genome sequencing for all samples was performed using a
Sanger sequencing method that we previously described [19].
The primers used for genome-wide amplification and
sequencing experiments are provided in this article [19]. In
brief, genome-wide amplification was completed using 19 RT-
PCRs and 39 sequencing reactions were carried out for
genome-wide sequencing, as published. All sequences were
assembled and verified using the ATF software, version
1.0.2.41 (Connexio Genomics, Perth, WA, Australia), using the
reference sequence influenza A/Nanjing/1/2009(H3N2) for all
segments (GenBank accession: GU907114- GU907117 and
GU907119-GU907121), except for the PB1 segment, for which
the reference sequence was influenza A/Sendai-H/
F193/2007(H3N2) (GenBank accession: AB441948). The
multiple A’s observed at the 3’end of the NA, NP, and PA
genes were checked carefully by visualization of the
sequencing chromatogram. All genome sequences generated
in this study have been subjected to the mosaic detection
procedure described by Lam et al. 2013 [18].
Sequence comparison
Differences in nucleotide sequences between clinical and
MDCK-cultured samples were identified by pairwise
comparison with a program written using Statistical Analysis
System 9, (SAS Institute Inc., Cary, NC, USA). Sequences of
the 20 culture replicates of influenza strain A/Singapore/
H2011.704/2011(H3N2) were aligned using BioEdit (version
7.1.3.0). The nucleotide and aa differences among the 20
replicates were identified by visual inspection.
Statistical analysis
The association of Ct values in the mutation-affected and
non-affected groups was examined with the 2 Sample T-test.
All the categorical variables were compared using Fisher’s
exact test. All the statistical analyses were performed using
IBM SPSS Statistics software version 19. P values of <0.05
were considered statistically significant.
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GISAID EpiFlu database investigation for the D151
mutation in NA
Sample source types of all the human influenza A/H3N2 viral
genome sequences that were available on the GISAID EpiFlu
database and collected from Jan 2004 to Dec 2012 (as of 15
August 2013) were examined individually. All missense
mutations occurring at residue 151 of the NA gene were
recorded with respect to these sample source types for
comparison to our study results.
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